Table 2 Information on MDM2 inhibitors that exhibit synergistic effects on anticancer immunotherapy
Inhibitor | Target | References | Cancer type | Mechanism for the synergistic effect on anticancer immunotherapy |
|---|---|---|---|---|
Nutlin-3(a) | MDM2-P53 interaction | [39] | HNSCC | The upregulation of HLA and CD4 + T cells-associated cytotoxicity is facilitated by Nutlin-3 |
[50] | NA | Nutlin-3 was found to facilitate the maturation process of DCs and to enhance the proliferation of CD4 + and CD8 + T cells that are stimulated by DCs | ||
[53] | Neuroblastoma | Nutlin-3a has been observed to increase the expression of NK-ARs, leading to an improvement in the efficacy of NK-mediated tumor cell killing | ||
NVP-CGM097 | MDM2-P53 interaction | [44] | Bladder cancer | The administration of NVP-CGM097 has been observed to elevate the serum level of IL-2 and IFN-γ, as well as increase the count of CD4 + T cells |
HDM201 | MDM2-P53 interaction | [49] | Colorectal cancer | HDM201 has been observed to enhance DCs count and increase the CD8 + T/Treg ratio, as well as elevating IL-2 concentration |
RG7388 | MDM2-P53 interaction | [49] | Colorectal cancer | RG7388 increases the concentration of IL-2 |
APG-115 | MDM2-P53 interaction | [48] | Colorectal cancer/Breast cancer | The stabilization of T-cell STAT5 and consequent activation of CD8 + T-cell-mediated antitumor immunity is facilitated by APG-115 |
[50] | Colorectal cancer | APG-115 suppresses M2 macrophage polarization, increases M1 macrophage polarization, and leads to CD4 + T-cell activation | ||
AMG-232 | MDM2-P53 interaction | [52] | Ovarian clear cell carcinoma | AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing |